Membrex™
Triple Negative Breast Cancer (TNBC)
Key Facts
About Metaclipse Therapeutics
Metaclipse Therapeutics is a private, preclinical-stage biotech based in San Diego, pioneering a novel platform of membrane-anchored biological adjuvants. The company's core technology aims to overcome limitations in immunotherapy and vaccinology by co-delivering antigens and adjuvants in a single particulate formulation, designed to elicit potent and specific immune activation. Its lead platform, Membrex™, is an autologous cancer vaccine slated for Phase 1 trials in 2025, while its VaxRex™ platform targets improved vaccines for infectious diseases like influenza and SARS-CoV-2. The company is pre-revenue and funded through grants like an NCI SBIR award, positioning it to advance its pipeline toward clinical proof-of-concept.
View full company profileAbout Metaclipse Therapeutics
Metaclipse Therapeutics is a private, preclinical-stage biotech based in San Diego, pioneering a novel platform of membrane-anchored biological adjuvants. The company's core technology aims to overcome limitations in immunotherapy and vaccinology by co-delivering antigens and adjuvants in a single particulate formulation, designed to elicit potent and specific immune activation. Its lead platform, Membrex™, is an autologous cancer vaccine slated for Phase 1 trials in 2025, while its VaxRex™ platform targets improved vaccines for infectious diseases like influenza and SARS-CoV-2. The company is pre-revenue and funded through grants like an NCI SBIR award, positioning it to advance its pipeline toward clinical proof-of-concept.
View full company profileAbout Metaclipse Therapeutics
Metaclipse Therapeutics is a private, preclinical-stage biotech based in San Diego, pioneering a novel platform of membrane-anchored biological adjuvants. The company's core technology aims to overcome limitations in immunotherapy and vaccinology by co-delivering antigens and adjuvants in a single particulate formulation, designed to elicit potent and specific immune activation. Its lead platform, Membrex™, is an autologous cancer vaccine slated for Phase 1 trials in 2025, while its VaxRex™ platform targets improved vaccines for infectious diseases like influenza and SARS-CoV-2. The company is pre-revenue and funded through grants like an NCI SBIR award, positioning it to advance its pipeline toward clinical proof-of-concept.
View full company profileAbout Metaclipse Therapeutics
Metaclipse Therapeutics is a private, preclinical-stage biotech based in San Diego, pioneering a novel platform of membrane-anchored biological adjuvants. The company's core technology aims to overcome limitations in immunotherapy and vaccinology by co-delivering antigens and adjuvants in a single particulate formulation, designed to elicit potent and specific immune activation. Its lead platform, Membrex™, is an autologous cancer vaccine slated for Phase 1 trials in 2025, while its VaxRex™ platform targets improved vaccines for infectious diseases like influenza and SARS-CoV-2. The company is pre-revenue and funded through grants like an NCI SBIR award, positioning it to advance its pipeline toward clinical proof-of-concept.
View full company profileTherapeutic Areas
Other Triple Negative Breast Cancer (TNBC) Drugs
| Drug | Company | Phase |
|---|---|---|
| FLAG-001 | FLAG Therapeutics | Preclinical |